107 related articles for article (PubMed ID: 29296517)
1. Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.
Högstrand K; Darmanin S; Forshell TP; Grandien A
Oncotarget; 2018 Apr; 9(30):21396-21410. PubMed ID: 29765548
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant chimeric antigen receptor therapy.
Smith M; Zakrzewski J; James S; Sadelain M
Blood; 2018 Mar; 131(10):1045-1052. PubMed ID: 29358181
[TBL] [Abstract][Full Text] [Related]
4. The Immune Landscape of Cancer.
Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang TH; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA; Ziv E; Culhane AC; Paull EO; Sivakumar IKA; Gentles AJ; Malhotra R; Farshidfar F; Colaprico A; Parker JS; Mose LE; Vo NS; Liu J; Liu Y; Rader J; Dhankani V; Reynolds SM; Bowlby R; Califano A; Cherniack AD; Anastassiou D; Bedognetti D; Mokrab Y; Newman AM; Rao A; Chen K; Krasnitz A; Hu H; Malta TM; Noushmehr H; Pedamallu CS; Bullman S; Ojesina AI; Lamb A; Zhou W; Shen H; Choueiri TK; Weinstein JN; Guinney J; Saltz J; Holt RA; Rabkin CS; ; Lazar AJ; Serody JS; Demicco EG; Disis ML; Vincent BG; Shmulevich I
Immunity; 2018 Apr; 48(4):812-830.e14. PubMed ID: 29628290
[TBL] [Abstract][Full Text] [Related]
5. Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
Winkler R; Piskor EM; Kosan C
Cells; 2022 Dec; 12(1):. PubMed ID: 36611833
[TBL] [Abstract][Full Text] [Related]
6. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
[TBL] [Abstract][Full Text] [Related]
7. Treatment of T-cell non-Hodgkin's lymphoma.
Evens AM; Gartenhaus RB
Curr Treat Options Oncol; 2004 Aug; 5(4):289-303. PubMed ID: 15233906
[TBL] [Abstract][Full Text] [Related]
8. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
9. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
Hilmenyuk T; Ruckstuhl CA; Hayoz M; Berchtold C; Nuoffer JM; Solanki S; Keun HC; Beavis PA; Riether C; Ochsenbein AF
Oncoimmunology; 2017; 7(1):e1365997. PubMed ID: 29296517
[TBL] [Abstract][Full Text] [Related]
10. CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
Jacob MC; Favre M; Lemarc'Hadour F; Sotto MF; Bonnefoix T; Sotto JJ; Bensa JC
Am J Hematol; 1992 Jan; 39(1):45-51. PubMed ID: 1531569
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
[TBL] [Abstract][Full Text] [Related]
12. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Spinner S; Crispatzu G; Yi JH; Munkhbaatar E; Mayer P; Höckendorf U; Müller N; Li Z; Schader T; Bendz H; Hartmann S; Yabal M; Pechloff K; Heikenwalder M; Kelly GL; Strasser A; Peschel C; Hansmann ML; Ruland J; Keller U; Newrzela S; Herling M; Jost PJ
Leukemia; 2016 Jul; 30(7):1520-30. PubMed ID: 27055871
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
Yang ZZ; Novak AJ; Ziesmer SC; Witzig TE; Ansell SM
Cancer Res; 2006 Oct; 66(20):10145-52. PubMed ID: 17047079
[TBL] [Abstract][Full Text] [Related]
14. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
[TBL] [Abstract][Full Text] [Related]
15. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
